SINGAPORE -- A new orchid hybrid in Singapore was named after President Yoon Suk Yeol and his wife Kim Keon Hee while Yoon ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Today, a brief rundown of news from Sanofi and Novo Nordisk, as well as updates from The Lasker Foundation, Edgewise Therapeutics and Vanda Pharmaceuticals that you may have missed. A growing cohort ...

MANILA, Philippines — An orchid exhibit inspired by the "Bahay Kubo" recently opened at the popular Singapore tourist destination Gardens by the Bay. Aptly titled "Gardens by the Bahay Kubo: A ...

Credit: mi_viri/Shutterstock. The US Food and Drug Administration (FDA) has declined to approve the new drug application (NDA) submitted by Vanda Pharmaceuticals for tradipitant to treat gastroparesis ...

Sept 19 (Reuters) - Vanda Pharmaceuticals (VNDA.O), opens new tab said on Thursday the U.S. Food and Drug Administration declined to approve its drug to treat a type of stomach condition that ...

Vanda Pharmaceuticals (NASDAQ:VNDA) fell ~9% in the premarket on Thursday after the U.S. FDA declined to approve its marketing application for experimental therapy, tradipitant for a stomach ...

WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program. Gastroparesis is a serious condition ...

The FDA flashed a red light on Van­da Phar­ma­ceu­ti­cals’ ex­per­i­men­tal treat­ment for a gas­troin­testi­nal con­di­tion that dis­rupts the di­ges­tion process.

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 trial that missed its primary endpoint. The biotech came out swinging after ...